4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects (scientific article)

Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines

Q24670108

Three fatal cases of PMA and PMMA poisoning in Denmark

Q28181364

Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics

Q28186645

1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists

Q28263375

CYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA)

Q28277977

"Research chemicals": tryptamine and phenethylamine use among high-risk youth.

Q30368441

Simultaneous determination of amphetamine derivatives in human urine after SPE extraction and HPLC-UV analysis.

Q30759663

Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of "hallucinogenic designer drugs" in urine of consumers.

Q33439214

Cerebral vasculopathy after 4-bromo-2,5-dimethoxyphenethylamine ingestion

Q34113831

Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up

Q34166349

Hallucinogen persisting perception disorder: what do we know after 50 years?

Q34180184

A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs

Q34313776

Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human

Q34375037

A study of the metabolism of methamphetamine and 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in isolated rat hepatocytes

Q34554009

A fatal poisoning involving Bromo-Dragonfly.

Q34906623

Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY.

Q35010509

MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder.

Q40028400

LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum

Q43196010

Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers

Q43567794

Psychometric assessment of the Hallucinogen Rating Scale.

Q43570042

3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics.

Q43830163

Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant.

Q43842082

Pattern of use and subjective effects of Salvia divinorum among recreational users.

Q43842086

Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers.

Q43842103

Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale

Q43842193

Postmortem Identification and Quantitation of 2,5-Dimethoxy-4-n-propylthiophenethylamine Using GC-MSD and GC-NPD

Q44648322

Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire

Q44959429

Disposition of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2-hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration

Q46703025

A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy

Q46889621

Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users

Q46899627

Subjective reports of the effects of MDMA in a clinical setting.

Q51207935

Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study.

Q55032917

Pharmacology of MDMA in Humans

Q56047788

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

2C-B

Q229942

P304

page(s)

1026-1035

P577

publication date

2012-01-09

P1433

published in

Journal of Psychopharmacology

Q6295819

P1476

title

4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects

P478

volume

Reverse relations

cites work (P2860)

Q55058151	"Hallucinations" Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs.
Q59218493	25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers
Q91635326	Acute Effects of 2C-E in Humans: An Observational Study
Q34674320	Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions
Q52316991	Acute Pharmacological Effects of 2C-B in Humans: An Observational Study.
Q34290962	Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats.
Q34535259	Clinical applications of hallucinogens: A review
Q58599010	Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs
Q30352297	Consumption of new psychoactive substances in a Spanish sample of research chemical users.
Q39989208	Drug testing in Europe: monitoring results of the Trans European Drug Information (TEDI) project
Q39548034	Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens.
Q89736148	Mephedrone and Alcohol Interactions in Humans
Q50464203	Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study.
Q52303973	New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon?
Q39402042	Patterns of use and toxicity of new para-halogenated substituted cathinones: 4-CMC (clephedrone), 4-CEC (4-chloroethcatinone) and 4-BMC (brephedrone).
Q89964458	Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics
Q92990121	Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis
Q48060529	Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis.